Vincent E. Gaillard

907 total citations
21 papers, 348 citations indexed

About

Vincent E. Gaillard is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Vincent E. Gaillard has authored 21 papers receiving a total of 348 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Hepatology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Vincent E. Gaillard's work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Colorectal Cancer Treatments and Studies (9 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Vincent E. Gaillard is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Colorectal Cancer Treatments and Studies (9 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Vincent E. Gaillard collaborates with scholars based in Switzerland, Germany and France. Vincent E. Gaillard's co-authors include Andrew X. Zhu, Peter R. Galle, Richard S. Finn, Arndt Vogel, Philippe Merle, Ann‐Lii Cheng, Alan Nicholas, Zhiqiang Meng, Sairy Hernandez and Paul Dillon and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Journal of Hepatology.

In The Last Decade

Vincent E. Gaillard

21 papers receiving 343 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vincent E. Gaillard Switzerland 10 229 170 75 74 66 21 348
Charlotte Maulat France 11 133 0.6× 163 1.0× 76 1.0× 75 1.0× 87 1.3× 33 385
Yan‐Jun Xiang China 11 232 1.0× 88 0.5× 69 0.9× 78 1.1× 35 0.5× 32 302
Zuan Lin China 9 107 0.5× 216 1.3× 86 1.1× 103 1.4× 27 0.4× 18 325
Maridi Aerts Belgium 8 143 0.6× 75 0.4× 88 1.2× 60 0.8× 26 0.4× 26 256
Fubao Liu China 10 111 0.5× 58 0.3× 61 0.8× 53 0.7× 30 0.5× 36 231
Malin Sternby Eilard Sweden 10 108 0.5× 129 0.8× 45 0.6× 81 1.1× 13 0.2× 27 314
M. Ikeda Japan 7 130 0.6× 241 1.4× 41 0.5× 229 3.1× 36 0.5× 19 410
Serene Shereef United States 8 71 0.3× 164 1.0× 110 1.5× 26 0.4× 21 0.3× 11 293
Kidist Yimam United States 9 197 0.9× 59 0.3× 108 1.4× 141 1.9× 21 0.3× 21 312
Lee Jenkins United States 6 173 0.8× 140 0.8× 72 1.0× 37 0.5× 11 0.2× 8 307

Countries citing papers authored by Vincent E. Gaillard

Since Specialization
Citations

This map shows the geographic impact of Vincent E. Gaillard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent E. Gaillard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent E. Gaillard more than expected).

Fields of papers citing papers by Vincent E. Gaillard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent E. Gaillard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent E. Gaillard. The network helps show where Vincent E. Gaillard may publish in the future.

Co-authorship network of co-authors of Vincent E. Gaillard

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent E. Gaillard. A scholar is included among the top collaborators of Vincent E. Gaillard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent E. Gaillard. Vincent E. Gaillard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cheon, Jaekyung, Jung Sun Kim, Beodeul Kang, et al.. (2024). Organ‐specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study. Liver International. 44(8). 1961–1970. 3 indexed citations
2.
Yang, Hannah, Beodeul Kang, Yeonjung Ha, et al.. (2023). High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma. JHEP Reports. 5(4). 100672–100672. 48 indexed citations
3.
Song, Young Shin, Hannah Yang, Beodeul Kang, et al.. (2023). Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma. Liver Cancer. 13(1). 89–98. 12 indexed citations
4.
Vogel, Arndt, Richard S. Finn, M. Lorraine Leibfried, et al.. (2023). Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis. Liver Cancer. 12(6). 510–520. 9 indexed citations
5.
Zhu, Andrew X., Farshid Dayyani, Chia‐Jui Yen, et al.. (2022). Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. Clinical Cancer Research. 28(16). 3537–3545. 75 indexed citations
6.
Foerster, Friedrich, Roman Kloeckner, María Reig, et al.. (2022). ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.. Journal of Clinical Oncology. 40(4_suppl). TPS498–TPS498. 16 indexed citations
7.
D’Alessio, Antonio, Arndt Weinmann, Peter R. Galle, et al.. (2022). Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study. Journal of Hepatology. 77. S376–S376. 2 indexed citations
8.
Vogel, Arndt, Lorenza Rimassa, Ghassan K. Abou‐Alfa, et al.. (2021). Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. Liver Cancer. 10(3). 240–248. 31 indexed citations
9.
10.
11.
12.
Kudo, Masatoshi, Masafumi Ikeda, Andrew X. Zhu, et al.. (2020). 169P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC. Annals of Oncology. 31. S1304–S1305. 4 indexed citations
13.
Al‐Batran, Salah‐Eddin, Christoph Maintz, Thorsten Oliver Goetze, et al.. (2020). Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. The Oncologist. 25(8). e1181–e1187. 15 indexed citations
14.
Vogel, Arndt, Lorenza Rimassa, Hui‐Chuan Sun, et al.. (2020). Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.. Journal of Clinical Oncology. 38(15_suppl). 4585–4585. 7 indexed citations
15.
Ikeda, Masafumi, Andrew X. Zhu, Si Qin, et al.. (2020). 1008P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC. Annals of Oncology. 31. S698–S699. 8 indexed citations
16.
Losem, Christoph, et al.. (2019). AVAiLABLE NIS – AVASTIN® in lung cancer treatment in routine oncology practice in Germany. BMC Cancer. 19(1). 433–433. 6 indexed citations
17.
Faehling, Martin, Johannes Achenbach, Peter Staib, et al.. (2018). Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC). Journal of Cancer Research and Clinical Oncology. 144(7). 1375–1383. 11 indexed citations
18.
Poizat, Germain, Vincent E. Gaillard, & Marc Durand. (2015). Une perspective d’éducation tout au long de la vie centrée sur l’activité humaine et positionnée dans le courant des Humanités Numériques. N° 17(1). 171–187. 1 indexed citations
19.
Wierzchoń, Michał, Vincent E. Gaillard, Dariusz Asanowicz, & Axel Cleeremans. (2012). Manipulating attentional load in sequence learning through random number generation. Advances in Cognitive Psychology. 8(2). 179–195. 9 indexed citations
20.
Gaillard, Vincent E., et al.. (2010). Proficiency in cardiopulmonary resuscitation of medical students at graduation: a simulator-based comparison with general practitioners. Swiss Medical Weekly. 140(304). 57–57. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charlotte Maulat Breakdown of academic impact, for papers by Yan‐Jun Xiang Breakdown of academic impact, for papers by Zuan Lin Breakdown of academic impact, for papers by Maridi Aerts Breakdown of academic impact, for papers by Fubao Liu Breakdown of academic impact, for papers by Malin Sternby Eilard Breakdown of academic impact, for papers by M. Ikeda Breakdown of academic impact, for papers by Serene Shereef Breakdown of academic impact, for papers by Kidist Yimam Breakdown of academic impact, for papers by Lee Jenkins
Rankless by CCL
2026